Reuters logo
GSK says heart drug darapladib fails in second late-stage trial
May 13, 2014 / 6:50 AM / 4 years ago

GSK says heart drug darapladib fails in second late-stage trial

LONDON (Reuters) - GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine.

A British Airways airplane flies past a signage for pharmaceutical giant GlaxoSmithKline (GSK) in London April 22, 2014. REUTERS/Luke MacGregor

Darapladib had already failed in a late-stage trial for patients with well-treated heart disease. [ID:nL1N0MR078]

Patrick Vallance, GSK’s President of Pharmaceuticals R&D, said he was disappointed that the outcome of the second phase III study did not support a regulatory submission.

“In the study, darapladib did not achieve the primary endpoint of a reduction of major coronary events versus placebo when added to standard of care,” the British company said on Tuesday.

Reporting by Paul Sandle; editing by Kate Holton

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below